LYNPARZA® (olaparib) - Official Patient Website
WEBLYNPARZA is an oral medicine that may be used to treat adults with advanced or recurrent ovarian, prostate, breast, pancreatic, or metastatic breast cancers with a certain type of abnormal BRCA or HRR gene. Learn more about how LYNPARZA works, its possible side effects, and patient support options.
Lynparza: Uses, Dosage, Side Effects & Warnings - Drugs.com
WEBOct 26, 2023 · Lynparza is a targeted cancer medicine that blocks PARP, a protein that helps some cancer cells repair themselves. It is used to treat specific types of ovarian, breast, pancreatic, and prostate cancers with certain genetic markers.
Lynparza (olaparib): What to Expect, Side Effects, and More
WEBLynparza is a targeted therapy that blocks DNA repair in cancer cells with a BRCA1 or BRCA2 mutation. Learn how it works, what to expect, side effects, and how to pay for it.
Lynparza (olaparib) - Uses, Side Effects, and More - WebMD
WEBLynparza oral is a medication used to treat certain cancers by slowing or stopping the growth of cancer cells. It can cause serious side effects such as nausea, vomiting, low blood...
Olaparib - Wikipedia
WEBOlaparib, sold under the brand name Lynparza, is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer and other cancers. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
Lynparza: Side Effects, Uses, Cost, Dosage, and More - Healthline
WEBMay 23, 2022 · Lynparza is a prescription drug that contains olaparib, a biologic drug that blocks specific enzymes in cancer cells. It’s used to treat metastatic castration-resistant prostate cancer, advanced...
Lynparza (olaparib): Side effects, cost, dosage, and more
WEBDec 17, 2021 · Lynparza is a brand-name drug that contains olaparib, a PARP inhibitor. It’s used to treat adults with BRCA-positive prostate, breast, ovarian, or pancreatic cancer. Learn about its side effects,...
What Is LYNPARZA® (olaparib)?
WEBLYNPARZA is a PARP inhibitor that targets cancer cell pathways and prevents DNA repair. It is used to treat ovarian, breast, pancreatic, and prostate cancers with abnormal BRCA or HRR genes.
FDA approves first treatment for breast cancer with a certain …
WEBThe U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer …
PARP Inhibitor for Advanced or Recurrent Ovarian Cancer – LYNPARZA …
WEBWARNINGS AND PRECAUTIONS. Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML): Occurred in approximately 1.2% of patients with various BRCAm, …
Skip to content